

FACSIMILE TRANSMITTAL
BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road
Suite 200
Menlo Park, California 94025
Telephone (650) 327-3400
Facsimile (650) 327-3231

FAX RECEIVED
JUL 10 2001
GROUP 1600

OFFICIAL

Date: July 10, 2001

To: **Examiner Grun**
U.S. Patent & Trademark Office
Washington, D.C.

Facsimile No.: (703) 308-4242

From: Paula A. Borden, Patent Agent
(650) 833-7710


Re: U.S. Patent Application No. 09/269,874
corresponding to International
Application No. PCT/EP97/05441
Filing Date: August 2, 1999
Inventor(s): Bujard
Title: RECOMBINANTS PROCESS FOR PREPARING A
COMPLETE MALARIA ANTIGEN, GP190/MSP1
Attorney Docket No.: GRUE-003

Message: **Copy of Our Response to Office Action dated
December 19, 2000 -- filed on January 19, 2001**

Total number of pages, including this cover sheet: 14

WARNING: This facsimile message and accompanying documents are intended only for the use of the addressee indicated above. Information that is privileged or otherwise confidential may be contained therein. If you are not the intended recipient, you are hereby notified that any dissemination, copying, review or use of the above message or the accompanying documents is strictly prohibited. If you have received this message in error, please notify us immediately by telephone or facsimile, and mail the original to us at the above address. Thank you.

#191B
7/12/01

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Mathew Ott		
Signature		Date	January 19, 2001
RESPONSE TO RESTRICTION REQUIREMENT AND NOTICE TO COMPLY AND PRELIMINARY AMENDMENT Address to: Assistant Commissioner for Patents Washington, D.C. 20231		Attorney Docket	GRUE-003
		First Named Inventor	Bujard
		Application Number	09/269,874
		Filing Date	August 2, 1999
		Group Art Unit	1641
		Examiner Name	J. Grun
		Title	Recombinants Process for Preparing a Complete Malaria Antigen, GP190/MSP1

Sir:

This is in response to the Office Action dated December 19, 2000, which set a one-month period for response, making this response due on or before January 19, 2001. Accordingly, this response is timely filed.

Restriction Requirement

In the Office Action dated December 19, 2000, the Examiner required election of one of the following groups of claims:

- Group I, including claims 42-49 and 53-57, directed to a method of producing a protein;
- Group II, including claims 50-52, directed to a method of producing a nucleotide sequence;
- Group III, including claims 58-69, 70-72, 73-78 and 81, directed to a group of related products (encoding nucleic acids, vectors comprising the nucleic acids, and host cells comprising the nucleic acids) sharing a technical feature (i.e., nucleic acids);
- Group IV, including claim 80, directed to a given product (vaccine composition);
- Group V, including claim 79, directed to a therapeutic method using a protein product; and
- Group VI, including claim 82, directed to a method of stabilizing a gene sequence.